azrxfwp_07222021
Free Writing Prospectus dated July 22, 2021
Filed pursuant to Rule 433
Relating to the Preliminary Prospectus Supplement dated July 22,
2021
Registration Statement No. 333-256476
AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0
Million
Boca Raton, FL – July 22, 2021 -- AzurRx BioPharma, Inc. (NASDAQ: AZRX),
(“AzurRx” or the “Company”), a clinical
stage biopharmaceutical company specializing in the development of
targeted, non-systemic therapies for gastrointestinal (GI)
diseases, announced today that, due to demand, the underwriter has
agreed to increase the size of the previously announced public
offering and purchase on a firm commitment basis 9,090,910 shares
of common stock of the Company, at a price to the public of $0.55
per share, less underwriting discounts and commissions. The closing
of the offering is expected to occur on or about July 27, 2021,
subject to satisfaction of customary closing
conditions.
H.C. Wainwright & Co. is acting as the sole book-running
manager for the offering.
The Company has granted to the underwriter a 30-day option to
purchase up to an additional 1,363,636 shares of common stock at
the public offering price, less underwriting discounts and
commissions. The gross proceeds to AzurRx, before deducting
underwriting discounts and commissions and offering expenses and
assuming no exercise of the underwriter’s option to purchase
additional common stock, are expected to be approximately $5.0
million. The Company intends to use the net proceeds from this
offering for milestone payments due under our license agreements
and for other general corporate purposes, which may include product
manufacturing, clinical development, acquisitions or investments in
complementary businesses, products or technologies, and/or
increases in working capital.
The shares of common stock are being offered by the Company
pursuant to a “shelf” registration statement on Form
S-3 (File No. 333-256476) previously filed with the Securities and
Exchange Commission (the “SEC”) on May 26, 2021, and
declared effective by the SEC on June 2, 2021. The offering of the
shares of common stock is being made only by means of a prospectus,
including a prospectus supplement, forming a part of the effective
registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to, and describing the terms of,
the offering have been filed with the SEC and are available on the
SEC’s website at http://www.sec.gov. A final prospectus
supplement and the accompanying prospectus relating to the offering
will be filed with the SEC and, upon filing, may be obtained on the
SEC’s website at http://www.sec.gov or by contacting H.C.
Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York,
NY 10022, by telephone at (212) 856-5711 or e-mail at
placements@hcwco.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage
biopharmaceutical company specializing in the development
of targeted, non-systemic therapies for gastrointestinal (GI)
diseases. The Company has a pipeline of three gut-restricted GI
assets. The lead therapeutic candidate is MS1819, a
recombinant lipase for the treatment of exocrine pancreatic
insufficiency (EPI) in patients with cystic fibrosis and chronic
pancreatitis, currently in two Phase 2 clinical trials.
AzurRx is launching two clinical programs in 2021 using
proprietary formulations of niclosamide, a pro-inflammatory pathway
inhibitor, FW-1022 for COVID-19 gastrointestinal infections,
and FW-420 for grade 1 Immune Checkpoint Inhibitor-Associated
Colitis and diarrhea in oncology patients. The Company is
headquartered in Boca Raton, Florida with clinical operations in
Hayward, California. For more information,
visit www.azurrx.com.
Forward-Looking Statements
This press release may contain certain statements relating to
future results which are forward-looking statements. These
statements are not historical facts, but instead represent only the
Company’s belief regarding future events, many of which, by
their nature, are inherently uncertain and outside of the
Company’s control. These forward-looking statements are
subject to risks and uncertainties including, among other things,
the completion of the public offering, the satisfaction of
customary closing conditions related to the public offering and the
intended use of proceeds from the public offering. It is possible
that the Company’s actual results and financial condition may
differ, possibly materially, from the anticipated results and
financial condition indicated in these forward-looking statements,
depending on factors including risks and uncertainties related to
market conditions; whether results obtained in preclinical and
nonclinical studies and clinical trials will be indicative of
results obtained in future clinical trials; whether preliminary or
interim results from a clinical trial will be indicative of the
final results of the trial; the size of the potential markets for
the Company’s drug candidates and its ability to service
those markets; and the Company’s current and future capital
requirements and its ability to raise additional funds to satisfy
its capital needs. Additional information concerning the Company
and its business, including a discussion of factors that could
materially affect the Company’s financial results, including
those related to the clinical development of its clinical assets,
the results of its clinical trials, and the impact of the
coronavirus (COVID-19) pandemic on the Company’s operations
and current and planned clinical trials, including, but not limited
to delays in clinical trial recruitment and participation, are
contained in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2020 under the heading “Risk
Factors,” as well as the Company’s subsequent
filings with the Securities and Exchange Commission. All
forward-looking statements included in this press release are made
only as of the date of this press release, and we do not undertake
any obligation to publicly update or correct any forward-looking
statements to reflect events or circumstances that subsequently
occur or of which we hereafter become aware.
For more information:
AzurRx BioPharma, Inc.
777 Yamato Road
Suite 502
Boca Raton, Florida 33431
Phone: (561) 589-7020
info@azurrx.com
Media contact:
Tiberend Strategic Advisors, Inc.
Johanna Bennett/Ingrid Mezo
(212) 375-2665/(646) 604-5150
jbennett@tiberend.com/imezo@tiberend.com